According to a new report published by , titled, “Multiplexed Diagnostics Market," The multiplexed diagnostics market was valued at $10.7 billion in 2022, and is estimated to reach $41.5 billion by 2032, growing at a CAGR of 14.5% from 2023 to 2032.

Multiplexed Diagnostics Market

Multiplexed diagnostics refers to a sophisticated technique used in medical and scientific fields to simultaneously analyze multiple parameters within a single diagnostic test. Multiplexed diagnostics allow for the parallel detection and quantification of various biomarkers, genes, proteins, or other analytes by combining several assays or tests into a single platform. This approach optimizes resource utilization, saves time, and reduces sample requirements, making it particularly valuable in high-throughput environments.

Key factors driving the growth of the multiplexed diagnostics market include a rise in prevalence of chronic disease, technological advancements in multiplexed diagnostics products and growing demand for personalized medicine.

The growth in demand for personalized medicine has fueled a significant expansion in the field of multiplexed diagnostics. There has been a steady rise in demand for personalized medicine due to its potential to improve patient outcomes and minimize adverse effects.

Moreover, the various advantages offered by multiplexed diagnostics such as cost effective, and time efficient over traditional single-marker tests are one of the major factors that propel the growth of the market. For instance, multiplexed diagnostics enable early disease detection, risk assessment, and treatment monitoring, which is especially critical in conditions such as cancer. The ability to simultaneously assess multiple biomarkers, such as genes, proteins, and metabolites, enhances diagnostic accuracy.

Furthermore, the pharmaceutical industry benefits from multiplexed diagnostics as it aids in patient stratification for clinical trials, enhancing drug development success rates. As a result, pharmaceutical companies have increasingly incorporated multiplexed diagnostics in their drug discovery and development processes. In addition, the surge in demand for personalized medicine is a driving force behind the rapid growth of multiplexed diagnostics. The ability to comprehensively analyze multiple biomarkers in a single sample aligns with the individualized treatment approach that personalized medicine advocates. Multiplexed diagnostics are poised to revolutionize healthcare by enabling earlier and more accurate diagnoses, tailoring treatments, with a projected exponential market growth, and improving patient outcomes.

The market also offers growth opportunities to the key players in the market. Multiplexed diagnostic technology is in demand because of its different therapeutic applications, such as it can be helpful for drug development and clinical trials and at the same time it can also be used in cancer and infectious disease monitoring. In addition, the surge in awareness regarding emerging applications of multiplexed diagnostics fuels the growth of the multiplexed diagnostics market.

Moreover, rise in the demand of personalized medicine and combining multiplexed diagnostic data with advanced data analytics and AI is expected to yield deeper insights and predictive models for disease outcomes and treatment responses, these are the factors that have increased the demand for multiplexed diagnostics and hence propel the growth of the market during the forecast period. For instance, according to a report published by Medical Device Network in January 2023, ALiA BioTech group has announced the deployment of its Lab-on-Chip diagnostic platform, which performs multiplex testing using a single biochip. The new next-generation rapid diagnostic platform can provide up to 30 results from a single drop of bodily fluid, such as blood, serum, swab, or urine, in 15 minutes. It integrates several laboratory functions in a single chip, which is a miniaturized diagnostic laboratory interface that has been specifically designed for point-of-care use.

Furthermore, in the surge in the application of multiplexed diagnostics in infectious disease management, multiplexed tests rapidly identify multiple pathogens causing similar symptoms, crucial for timely and accurate disease control. This was particularly highlighted during the COVID-19 pandemic, where multiplexed diagnostic platforms were rapidly developed to simultaneously detect SARS-CoV-2 and other respiratory viruses. Thus, all these factors are collectively expected to open new avenues for the growth of the multiplexed diagnostics market during the forecast period.

The multiplexed diagnostics market is segmented into product type, application, end user, and region. Based on product type, the market is bifurcated into instruments & accessories and kits & reagents. Based on application, it is segregated into infectious disease, oncology, autoimmune disease, cardiac disease, allergies, and others. Based on end user, it is segmented into hospitals, diagnostic centers, and others. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Market Insights

By product type, the kits & reagents segment is expected to experience rapid growth in the market and is estimated to reach $24,091.95 million by 2032, with a CAGR of 14.8%. However, the instruments & accessories segment is estimated to be growing with a significant CAGR of 14.1% during the forecast period.

By application, the infectious disease segment dominated the global market. However, the autoimmune disorders segment is expected to grow with a significant CAGR of 14.7% during the forecast period.

By end user, the hospitals segment dominated the global market. However, the diagnostics centers segment is expected to grow with a significant CAGR of 14.2% during the forecast period.

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 15.6% during the forecast period.

Overview

The global multiplexed diagnostics market was valued at $10.7 billion in 2022, and is projected to reach $41.5 billion by 2032, growing at a CAGR of 14.5% from 2023 to 2032.Multiplexing is the process of simultaneously detecting or identifying multiple biomarkers in a single diagnostic test, which can be valuable for several different types of diseases. For instance, pharmacogenomic studies in patients with cardiovascular disease have indicated that the presence of polymorphisms affects response of a patient to various drugs. The multiplex detection of relevant biomarkers, hence, not only provides insight into the pathophysiology of cardiovascular disease, but also serves as a guide for the most efficient treatment option.

In addition, multiplex tests simultaneously analyze samples for multiple pathogens. Currently, available multiplex tests, including those from the life sciences company Thermo Fisher Scientific, leverage PCR techniques to selectively amplify genes specific to each virus of interest. For SARS-CoV-2, the test might amplify genes that code for the envelope protein (E gene) of the virus or the nucleocapsid protein (N gene). Targets may include virus specific matrix proteins as well as nucleocapsid proteins for Influenza A, B, and Respiratory syncytial virus (RSV), polymerase chain reaction (PCR).

Major factors that drive the growth of the global multiplexed diagnostics market include an increase in need for automated equipment and varied analytical methodologies, increase in incidence of disease outbreaks such as coronavirus and Ebola virus, and surge in technological innovations in assay design, detection methods, and data analysis techniques.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, cardiovascular diseases, and autoimmune disorders are the major factors that increase the demand for multiplexed diagnostics tests kits and instruments and hence propel the growth of the market.

In addition, the increase in the number of key market players and the strategies they adopt for the development of technologically advanced multiplexed diagnostics products are the major factors that boost the growth of the multiplexed diagnostics market. For instance, in January 2023, Agilent Technologies, Inc. announced a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis and to commercialize workflow solutions for multiplex assays in the clinical research market. Integrating Dako Omnis (auto-staining instrument) of Agilent and PhenoImager HT (imaging platform) of Akoya for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays create a singular end-to-end commercial workflow, including reagents, staining, imaging, and analysis.

However, the high cost associated with multiplexed diagnostic assay, and lack of skilled professionals to operate diagnostic tools and conduct multiplexed diagnostic assay restrain the growth of the multiplexed diagnostics market. On the contrary, the surge in the demand for novel home health monitoring systems such as increase in demand for xPOCT devices, which ensure the quality and performance requirements of in vitro diagnostics, performed in a short period by non-experts and increased use of personalized medicine are expected to provide additional opportunities for the multiplexed diagnostics market to grow during the forecast period.

The multiplexed diagnostics market is segmented into product type, application, end user, and region. On the basis of product type, the market is bifurcated into instruments & accessories and kits & reagents. On the basis of application, it is segregated into infectious disease, oncology, autoimmune disease, cardiac disease, allergies, and others. On the basis of end user, it is segmented into hospitals, diagnostic centers, and others. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Co-Diagnostics, Inc. Agilent Technologies, Inc., bioMérieux SA, Illumina Inc., Hologic, Inc. Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., and DiaSorin S.p.A. The key players such as bioMérieux SA, Hologic, Inc. F. Hoffmann-La Roche Ltd., Agilent Technologies Inc, Bio-Rad Laboratories and DiaSorin S.p.A have adopted product launch, product approval, acquisition, and partnership as major developmental strategies to improve the product portfolio.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the multiplexed diagnostics market analysis from 2022 to 2032 to identify the prevailing multiplexed diagnostics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the multiplexed diagnostics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global multiplexed diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

○ Co-Diagnostics, Inc

Scope of Multiplexed Diagnostics Market Report

Report Metric	Details
Report Name	Multiplexed Diagnostics Market
Accounted market size in 2022	$ 10.7 in billion
Forecasted market size in 2032	$ 41.5 billion
CAGR	14.5%
Base Year	2022
Forecasted years	2024 - 2032
By Product Type	● Instruments and Accessories ● Kits and Reagents
By Application	● Infectious Disease ● Oncology ● Autoimmune Diseases ● Cardiac Diseases ● Allergies ● Others
By End User	● Hospitals ● Diagnostic Centers ● Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
● New Product Development/ Product Matrix of Key Players	● Regulatory Guidelines, ● Additional company profiles with specific to client's interest, ● Additional country or region analysis- market size and forecast, ● Average Selling Price Analysis / Price Point Analysis, ● Expanded list for Company Profiles, ● Historic market data, ● SWOT Analysis, Key Market Segments
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

How fast is Multiplexed Diagnostics Market growing?

Ans: The Multiplexed Diagnostics Market witnessing a CAGR of 14.5% during the forecast period 2024-2032.

What is the Multiplexed Diagnostics Market size in 2032?

Ans: The Multiplexed Diagnostics Market size in 2032 will be $ 41.5 billion.

Who are the main players in the Multiplexed Diagnostics Market report?

Ans: The main players in the Multiplexed Diagnostics Market are ● Regulatory Guidelines, ● Additional company profiles with specific to client's interest, ● Additional country or region analysis- market size and forecast, ● Average Selling Price Analysis / Price Point Analysis, ● Expanded list for Company Profiles, ● Historic market data, ● SWOT Analysis, Key Market Segments

What are the Application segmentation covered in the Multiplexed Diagnostics Market report?

Ans: The Applications covered in the Multiplexed Diagnostics Market report are ● Infectious Disease, ● Oncology, ● Autoimmune Diseases, ● Cardiac Diseases, ● Allergies, ● Others

What are the Type segmentation covered in the Multiplexed Diagnostics Market report?

Ans: The Types covered in the Multiplexed Diagnostics Market report are ● Instruments and Accessories, ● Kits and Reagents

What are the End User segmentation covered in the Multiplexed Diagnostics Market report?

Ans: The End users covered in the Multiplexed Diagnostics Market report are ● Hospitals, ● Diagnostic Centers, ● Others

CHAPTER 1: INTRODUCTION

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growth in demand for personalized medicine

3.4.1.2. Rise in prevalence of chronic disease

3.4.1.3. Technological advancements in multiplexed diagnostics products

3.4.2. Restraints

3.4.2.1. High cost associated with multiplexed diagnostics

3.4.3. Opportunities

3.4.3.1. Expansion of applications of multiplexed diagnostics

CHAPTER 4: MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Instruments and Accessories

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Kits and Reagents

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

CHAPTER 5: MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Infectious Disease

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Oncology

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Autoimmune Diseases

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

5.5. Cardiac Diseases

5.5.1. Key market trends, growth factors and opportunities

5.5.2. Market size and forecast, by region

5.5.3. Market share analysis by country

5.6. Allergies

5.6.1. Key market trends, growth factors and opportunities

5.6.2. Market size and forecast, by region

5.6.3. Market share analysis by country

5.7. Others

5.7.1. Key market trends, growth factors and opportunities

5.7.2. Market size and forecast, by region

5.7.3. Market share analysis by country

CHAPTER 6: MULTIPLEXED DIAGNOSTICS MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Diagnostic Centers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Others

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

CHAPTER 7: MULTIPLEXED DIAGNOSTICS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key market trends, growth factors and opportunities

7.2.2. Market size and forecast, by Product Type

7.2.3. Market size and forecast, by Application

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Market size and forecast, by Product Type

7.2.5.1.2. Market size and forecast, by Application

7.2.5.1.3. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Market size and forecast, by Product Type

7.2.5.2.2. Market size and forecast, by Application

7.2.5.2.3. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Market size and forecast, by Product Type

7.2.5.3.2. Market size and forecast, by Application

7.2.5.3.3. Market size and forecast, by End User

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities

7.3.2. Market size and forecast, by Product Type

7.3.3. Market size and forecast, by Application

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Market size and forecast, by Product Type

7.3.5.1.2. Market size and forecast, by Application

7.3.5.1.3. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Market size and forecast, by Product Type

7.3.5.2.2. Market size and forecast, by Application

7.3.5.2.3. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Market size and forecast, by Product Type

7.3.5.3.2. Market size and forecast, by Application

7.3.5.3.3. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Market size and forecast, by Product Type

7.3.5.4.2. Market size and forecast, by Application

7.3.5.4.3. Market size and forecast, by End User

7.3.5.5. Spain

7.3.5.5.1. Market size and forecast, by Product Type

7.3.5.5.2. Market size and forecast, by Application

7.3.5.5.3. Market size and forecast, by End User

7.3.5.6. Rest of Europe

7.3.5.6.1. Market size and forecast, by Product Type

7.3.5.6.2. Market size and forecast, by Application

7.3.5.6.3. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities

7.4.2. Market size and forecast, by Product Type

7.4.3. Market size and forecast, by Application

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Market size and forecast, by Product Type

7.4.5.1.2. Market size and forecast, by Application

7.4.5.1.3. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Market size and forecast, by Product Type

7.4.5.2.2. Market size and forecast, by Application

7.4.5.2.3. Market size and forecast, by End User

7.4.5.3. Australia

7.4.5.3.1. Market size and forecast, by Product Type

7.4.5.3.2. Market size and forecast, by Application

7.4.5.3.3. Market size and forecast, by End User

7.4.5.4. India

7.4.5.4.1. Market size and forecast, by Product Type

7.4.5.4.2. Market size and forecast, by Application

7.4.5.4.3. Market size and forecast, by End User

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Product Type

7.4.5.5.2. Market size and forecast, by Application

7.4.5.5.3. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Product Type

7.4.5.6.2. Market size and forecast, by Application

7.4.5.6.3. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Product Type

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Product Type

7.5.5.1.2. Market size and forecast, by Application

7.5.5.1.3. Market size and forecast, by End User

7.5.5.2. Saudi Arabia

7.5.5.2.1. Market size and forecast, by Product Type

7.5.5.2.2. Market size and forecast, by Application

7.5.5.2.3. Market size and forecast, by End User

7.5.5.3. South Africa

7.5.5.3.1. Market size and forecast, by Product Type

7.5.5.3.2. Market size and forecast, by Application

7.5.5.3.3. Market size and forecast, by End User

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Market size and forecast, by Product Type

7.5.5.4.2. Market size and forecast, by Application

7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction

8.2. Top winning strategies

8.3. Product mapping of top 10 player

8.4. Competitive dashboard

8.5. Competitive heatmap

8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Co-Diagnostics, Inc.

9.1.1. Company overview

9.1.2. Key executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.2. F. Hoffmann-La Roche Ltd.

9.2.1. Company overview

9.2.2. Key executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Agilent Technologies, Inc.

9.3.1. Company overview

9.3.2. Key executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. BioMerieux SA

9.4.1. Company overview

9.4.2. Key executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Illumina Inc.

9.5.1. Company overview

9.5.2. Key executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Hologic Inc.

9.6.1. Company overview

9.6.2. Key executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Thermo Fisher Scientific Inc.

9.7.1. Company overview

9.7.2. Key executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Bio-Rad Laboratories Inc

9.8.1. Company overview

9.8.2. Key executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.8.7. Key strategic moves and developments

9.9. Siemens Healthineers AG

9.9.1. Company overview

9.9.2. Key executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Diasorin S.p.A.

9.10.1. Company overview

9.10.2. Key executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

FEATURED COMPANIES

Agilent Technologies Inc

Hologic Inc

Thermo Fisher Scientific Inc

Siemens Healthineers AG

BioMerieux SA

F Hoffmann La Roche Ltd

DiaSorin

Illumina Inc

Bio-Rad Laboratories Inc

Co-Diagnostics, Inc.

LIST OF TABLES

TABLE 01. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 02. MULTIPLEXED DIAGNOSTICS MARKET FOR INSTRUMENTS AND ACCESSORIES, BY REGION, 2022-2032 ($MILLION)

TABLE 03. MULTIPLEXED DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)

TABLE 04. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 05. MULTIPLEXED DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2022-2032 ($MILLION)

TABLE 06. MULTIPLEXED DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)

TABLE 07. MULTIPLEXED DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)

TABLE 08. MULTIPLEXED DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY REGION, 2022-2032 ($MILLION)

TABLE 09. MULTIPLEXED DIAGNOSTICS MARKET FOR ALLERGIES, BY REGION, 2022-2032 ($MILLION)

TABLE 10. MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 11. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 12. MULTIPLEXED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. MULTIPLEXED DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2022-2032 ($MILLION)

TABLE 14. MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 15. MULTIPLEXED DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 18. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 19. NORTH AMERICA MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 20. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 21. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 22. U.S. MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 23. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 24. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 25. CANADA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 26. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 27. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 28. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 29. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 30. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 31. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 32. EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 33. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 34. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 35. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 36. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 37. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 38. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 39. UK MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 40. UK MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 41. UK MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 42. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 43. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 44. ITALY MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 45. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 46. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 47. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 48. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 49. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 50. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 52. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 53. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 54. ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 55. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 56. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 57. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 58. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 59. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 60. CHINA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 61. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 62. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 63. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 64. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 65. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 66. INDIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 67. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 68. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 69. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 70. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 71. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 72. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 73. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 74. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 75. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 76. LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 77. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 78. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 79. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 80. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 81. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 82. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 83. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 84. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 85. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 86. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 87. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 88. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 89. CO-DIAGNOSTICS, INC.: KEY EXECUTIVES

TABLE 90. CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT

TABLE 91. CO-DIAGNOSTICS, INC.: PRODUCT SEGMENTS

TABLE 92. CO-DIAGNOSTICS, INC.: PRODUCT PORTFOLIO

TABLE 93. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 94. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 96. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES

TABLE 98. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES

TABLE 99. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT

TABLE 100. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS

TABLE 101. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO

TABLE 102. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES

TABLE 103. BIOMERIEUX SA: KEY EXECUTIVES

TABLE 104. BIOMERIEUX SA: COMPANY SNAPSHOT

TABLE 105. BIOMERIEUX SA: PRODUCT SEGMENTS

TABLE 106. BIOMERIEUX SA: PRODUCT PORTFOLIO

TABLE 107. BIOMERIEUX SA: KEY STRATERGIES

TABLE 108. ILLUMINA INC.: KEY EXECUTIVES

TABLE 109. ILLUMINA INC.: COMPANY SNAPSHOT

TABLE 110. ILLUMINA INC.: PRODUCT SEGMENTS

TABLE 111. ILLUMINA INC.: PRODUCT PORTFOLIO

TABLE 112. HOLOGIC INC.: KEY EXECUTIVES

TABLE 113. HOLOGIC INC.: COMPANY SNAPSHOT

TABLE 114. HOLOGIC INC.: PRODUCT SEGMENTS

TABLE 115. HOLOGIC INC.: PRODUCT PORTFOLIO

TABLE 116. HOLOGIC INC.: KEY STRATERGIES

TABLE 117. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES

TABLE 118. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

TABLE 119. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS

TABLE 120. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO

TABLE 121. BIO-RAD LABORATORIES INC: KEY EXECUTIVES

TABLE 122. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 123. BIO-RAD LABORATORIES INC: PRODUCT SEGMENTS

TABLE 124. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 125. BIO-RAD LABORATORIES INC: KEY STRATERGIES

TABLE 126. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES

TABLE 127. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT

TABLE 128. SIEMENS HEALTHINEERS AG: PRODUCT SEGMENTS

TABLE 129. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

TABLE 130. DIASORIN S.P.A.: KEY EXECUTIVES

TABLE 131. DIASORIN S.P.A.: COMPANY SNAPSHOT

TABLE 132. DIASORIN S.P.A.: PRODUCT SEGMENTS

TABLE 133. DIASORIN S.P.A.: PRODUCT PORTFOLIO

TABLE 134. DIASORIN S.P.A.: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF MULTIPLEXED DIAGNOSTICS MARKET,2022-2032

FIGURE 03. TOP IMPACTING FACTORS IN MULTIPLEXED DIAGNOSTICS MARKET (2022 TO 2032)

FIGURE 04. TOP INVESTMENT POCKETS IN MULTIPLEXED DIAGNOSTICS MARKET (2023-2032)

FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 06. LOW THREAT OF NEW ENTRANTS

FIGURE 07. LOW THREAT OF SUBSTITUTES

FIGURE 08. LOW INTENSITY OF RIVALRY

FIGURE 09. LOW BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL MULTIPLEXED DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. MULTIPLEXED DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR INSTRUMENTS AND ACCESSORIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. MULTIPLEXED DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR ONCOLOGY, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR ALLERGIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. MULTIPLEXED DIAGNOSTICS MARKET, BY END USER, 2022 AND 2032(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF MULTIPLEXED DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 25. MULTIPLEXED DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)

FIGURE 26. U.S. MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 27. CANADA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 28. MEXICO MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 29. GERMANY MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 30. FRANCE MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 31. UK MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 32. ITALY MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 33. SPAIN MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 34. REST OF EUROPE MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 35. JAPAN MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 36. CHINA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 37. AUSTRALIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 38. INDIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 39. SOUTH KOREA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 40. REST OF ASIA-PACIFIC MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 41. BRAZIL MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 42. SAUDI ARABIA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 43. SOUTH AFRICA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 44. REST OF LAMEA MULTIPLEXED DIAGNOSTICS MARKET, 2022-2032 ($MILLION)

FIGURE 45. TOP WINNING STRATEGIES, BY YEAR (2021-2023)

FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)

FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)

FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 49. COMPETITIVE DASHBOARD

FIGURE 50. COMPETITIVE HEATMAP: MULTIPLEXED DIAGNOSTICS MARKET

FIGURE 51. TOP PLAYER POSITIONING, 2022

FIGURE 52. CO-DIAGNOSTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 55. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 56. AGILENT TECHNOLOGIES, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)

FIGURE 57. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 58. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 59. BIOMERIEUX SA: NET SALES, 2020-2022 ($MILLION)

FIGURE 60. BIOMERIEUX SA: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 61. BIOMERIEUX SA: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 62. ILLUMINA INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 63. ILLUMINA INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 64. ILLUMINA INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 65. HOLOGIC INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 66. HOLOGIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 67. HOLOGIC INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 68. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 69. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 70. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 71. BIO-RAD LABORATORIES INC: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 72. BIO-RAD LABORATORIES INC: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 73. BIO-RAD LABORATORIES INC: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 74. SIEMENS HEALTHINEERS AG: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 75. SIEMENS HEALTHINEERS AG: REVENUE SHARE BY SEGMENT, 2021 (%)

FIGURE 76. SIEMENS HEALTHINEERS AG: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 77. DIASORIN S.P.A.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 78. DIASORIN S.P.A.: REVENUE SHARE BY REGION, 2021 (%

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$5730

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$6450

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9600

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

DataPack

Electronic (PDF)

$3840

This license just provides quantitative data in a excel sheet

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions